Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad309 ↗Kurz gefasst
Leserbrief in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Rahul S Dalal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Rahul S Dalal, Jessica R Allegretti
Zitieren
APA
Dalal, R. S., & Allegretti, J. R. (2024). Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad309
Vancouver
Dalal RS, Allegretti JR. Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad309
BibTeX
@article{Dalal2024,
author = {Dalal, Rahul S and Allegretti, Jessica R},
title = {Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad309}
}
EUVIMED